139 related articles for article (PubMed ID: 9354926)
21. Karyometry in the early detection and chemoprevention of intraepithelial lesions.
Ranger-Moore J; Alberts DS; Montironi R; Garcia F; Davis J; Frank D; Brewer M; Mariuzzi GM; Bartels HG; Bartels PH
Eur J Cancer; 2005 Sep; 41(13):1875-88. PubMed ID: 16087328
[TBL] [Abstract][Full Text] [Related]
22. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
23. Digital image analysis of breast epithelial cells collected by random periareolar fine-needle aspirates (RPFNA) from women at high risk for breast cancer taking hormone replacement and the aromatase inhibitor, letrozole, for six months.
Frank DH; Kimler BF; Fabian CJ; Ranger-Moore J; Yozwiak M; Bartels HG; Alberts DS; Bartels PH
Breast Cancer Res Treat; 2009 Jun; 115(3):661-8. PubMed ID: 19125322
[TBL] [Abstract][Full Text] [Related]
24. Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.
Lippman SM; Lee JJ
Cancer Res; 2006 Mar; 66(6):2893-903. PubMed ID: 16540634
[TBL] [Abstract][Full Text] [Related]
25. Development of difluoromethylornithine (DFMO) as a chemoprevention agent.
Meyskens FL; Gerner EW
Clin Cancer Res; 1999 May; 5(5):945-51. PubMed ID: 10353725
[TBL] [Abstract][Full Text] [Related]
26. Diet and cancer: the disconnect between epidemiology and randomized clinical trials.
Meyskens FL; Szabo E
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1366-9. PubMed ID: 15941942
[TBL] [Abstract][Full Text] [Related]
27. Progress in clinical chemoprevention.
Kelloff GJ; Hawk ET; Karp JE; Crowell JA; Boone CW; Steele VE; Lubet RA; Sigman CC
Semin Oncol; 1997 Apr; 24(2):241-52. PubMed ID: 9129692
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer chemoprevention trials using the fine-needle aspiration model.
Kimler BF; Fabian CJ; Wallace DD
J Cell Biochem Suppl; 2000; 34():7-12. PubMed ID: 10762008
[TBL] [Abstract][Full Text] [Related]
29. Biological relevance of adduct detection to the chemoprevention of cancer.
Sharma RA; Farmer PB
Clin Cancer Res; 2004 Aug; 10(15):4901-12. PubMed ID: 15297390
[TBL] [Abstract][Full Text] [Related]
30. Nuclear cytometric changes in breast carcinogenesis.
Mommers EC; Poulin N; Sangulin J; Meijer CJ; Baak JP; van Diest PJ
J Pathol; 2001 Jan; 193(1):33-9. PubMed ID: 11169513
[TBL] [Abstract][Full Text] [Related]
31. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
Armstrong WB; Taylor TH; Meyskens FL
Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
[No Abstract] [Full Text] [Related]
32. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
Kelloff GJ; Lippman SM; Dannenberg AJ; Sigman CC; Pearce HL; Reid BJ; Szabo E; Jordan VC; Spitz MR; Mills GB; Papadimitrakopoulou VA; Lotan R; Aggarwal BB; Bresalier RS; Kim J; Arun B; Lu KH; Thomas ME; Rhodes HE; Brewer MA; Follen M; Shin DM; Parnes HL; Siegfried JM; Evans AA; Blot WJ; Chow WH; Blount PL; Maley CC; Wang KK; Lam S; Lee JJ; Dubinett SM; Engstrom PF; Meyskens FL; O'Shaughnessy J; Hawk ET; Levin B; Nelson WG; Hong WK;
Clin Cancer Res; 2006 Jun; 12(12):3661-97. PubMed ID: 16778094
[TBL] [Abstract][Full Text] [Related]
33. Nuclear texture: can it be used as a surrogate endpoint biomarker?
Palcic B
J Cell Biochem Suppl; 1994; 19():40-6. PubMed ID: 7823604
[TBL] [Abstract][Full Text] [Related]
34. Properties of intraepithelial neoplasia relevant to cancer chemoprevention and to the development of surrogate end points for clinical trials.
Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
Proc Soc Exp Biol Med; 1997 Nov; 216(2):151-65. PubMed ID: 9349684
[TBL] [Abstract][Full Text] [Related]
35. Clinical trials with retinoids for breast cancer chemoprevention.
Zanardi S; Serrano D; Argusti A; Barile M; Puntoni M; Decensi A
Endocr Relat Cancer; 2006 Mar; 13(1):51-68. PubMed ID: 16601279
[TBL] [Abstract][Full Text] [Related]
36. Single cell multiple biomarker analysis in archival breast fine-needle aspiration specimens: quantitative fluorescence image analysis of DNA content, p53, and G-actin as breast cancer biomarkers.
Rao JY; Apple SK; Hemstreet GP; Jin Y; Nieberg RK
Cancer Epidemiol Biomarkers Prev; 1998 Nov; 7(11):1027-33. PubMed ID: 9829712
[TBL] [Abstract][Full Text] [Related]
37. An evidence-based approach to cancer prevention clinical trials.
Greenwald P; McDonald SS; Anderson DE
Eur J Cancer Prev; 2002 Aug; 11 Suppl 2():S43-7. PubMed ID: 12570334
[TBL] [Abstract][Full Text] [Related]
38. Intermediate effect markers for colorectal cancer.
Baron JA
IARC Sci Publ; 2001; 154():113-29. PubMed ID: 11220651
[TBL] [Abstract][Full Text] [Related]
39. Strategies for phase II cancer chemoprevention trials: cervix, endometrium, and ovary.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1995; 23():1-9. PubMed ID: 8747372
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers for breast cancer.
Beenken SW; Bland KI
Minerva Chir; 2002 Aug; 57(4):437-48. PubMed ID: 12145573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
